EP says no to patents on breeding
Enlarge image


EP says no to patents on breeding

11.05.2012 - The European Parliament has adopted a non-binding resolution to exempt conventionally-bred plants or animals from patents.

Strasbourg – Although these patents are an important tool for the transfer of technology, the Parliament fears that "excessively broad patent protection can hamper innovation and progress and become detrimental to small and medium breeders by blocking access to animal and plant genetic resources". Therefore, the Parliament called on the European Patent Office to exclude products derived from conventional breeding, such as anti-carcinogenic broccoli or high-yield dairy cows, and all conventional breeding methods from patenting. It also wants the Commission and the Member States to ensure that the EU continues to exempt breeders from its patent law on plant and animal breeding. The non-legislative resolution was adopted by 354 votes to 192, with 22 abstentions.

“This is a huge success for all farmers, breeders and consumers who are concerned about the monopolisation of our food resources,” says Ruth Tippe from the coalition “No Patents On Seeds!“. Despite this, industry experts warn, that the motion might hamper the development of genetically modified crops or animals. The European Parliament therefore asked the European Commission to report “on the development and implications of patent law in the field of biotechnology and genetic engineering“ and to examine the impact of the patenting of breeding methods on the breeding and food industry.

The relevant European patent law dates from 1998. De jure it is impossible to receive patent protection for conventionally bred or genetically modified plant and animal varieties. Environmental Groups such as No Patents On Seeds claim that there is a loophole however: In the past, the European Patent Office protected gm-modified crops on the grounds that only the breeding process could not be patented, but the product regardless.


24.11.2015 After weeks of speculation it is official: US pharma major Pfizer and Irish Botox maker Allergan will merge. With the deal, Pfizer is planning to dodge the high US taxes, causing indignation among US politicians.


23.11.2015 Amidst talk of the IPO window closing and cancelled flotations, diagnostics firms are still striking a chord with investors. Swedish Immunovia and German Curetis are successfully raising public money.


20.11.2015 French Sanofi and British AstraZeneca are giving open innovation a go: The two pharma giants will exchange thousands of compounds – for free.


19.11.2015 French gene editing company Cellectis has granted Servier the rights to bring cancer immunotherapy UCART19 to market. Servier in turn has teamed up with Pfizer to hurry development along.


17.11.2015 The first Italian accelerator specifically for biotech projects has been launched with help from Sofinnova Partners. The plan of BiovelocITA: to help Italy grow into one of Europe’s strongest biotech markets.


13.11.2015 Scientists in Bath, UK, have developed a medical dressing that turns fluorescent green when it detects infection. The researchers hope that the smart burns dressing will help fight antibiotic resistance.


13.11.2015 Out with the old: Roche is discarding four sites with 1,200 staff in an effort to restructure its manufacturing network for small molecules. Instead, a new manufacturing site will be built in Switzerland.


10.11.2015 Algae have many skills, but cancer fighting was not one of them – until now. Researchers from Australia and Germany have genetically engineered diatom algae to accurately deliver chemotherapeutic drugs.


10.11.2015 AstraZeneca has plucked Californian biopharma company ZS Pharma from under Actelion’s nose. The UK company is paying US$2.7bn (€2.5bn) to acquire ZS and its promising hyperkalaemia treatment currently under US regulatory review.


04.11.2015 What biotech stock market slump? Despite all odds, 2015 is set to become a new record year for the European public biotech sector, according to a BIOCOM-study presented at BIO Europe in Munich.


All Events


Strasbourg (F)

BioFIT 2015

Current issue

All issues

Product of the week


Stock list

All quotes


  • SERODUS (N)2.67 NOK9.43%
  • VERONA PHARMA (UK)3.03 GBP8.21%


  • BIOFRONTERA (D)1.70 EUR-12.82%
  • DIAMYD MEDICAL -B- (S)9.30 SEK-11.43%
  • IMMUPHARMA (UK)23.00 GBP-6.12%


  • PLETHORA (UK)5.50 GBP83.3%
  • PROTHENA PLC (IE)70.04 USD42.0%
  • IMMUNICUM AB (S)43.10 SEK33.4%


  • EPIGENOMICS (D)1.85 EUR-61.4%
  • EVOCUTIS (UK)0.10 GBP-28.6%


  • KARO BIO (S)38.40 SEK5233.3%
  • CHRONTECH PHARMA (S)0.34 SEK1600.0%
  • GALAPAGOS (B)46.40 EUR269.7%


  • BIOTEST (D)15.25 EUR-80.8%
  • NEOVACS (F)0.72 EUR-78.1%

No liability assumed, Date: 24.11.2015